[Therapeutic monoclonal antibodies in clinical neurology].
Recombinant monoclonal antibodies break new ground in the treatment of immune-mediated nerve and muscle disorders but also of neurodegenerative diseases, in the field of neuro-oncology and in pain therapy, as they allow molecular targeting of defined cell populations or key pathophysiological molecules. However, safety risks might accompany a high efficacy. Basic understanding of this increasingly important class of agents and a steady update of knowledge, in particular on safety aspects, are therefore key requirements for responsible use based on an individual benefit-risk assessment.
Klinische Forschungsgruppe MS und Neuroimmunologie, Neurologische Klinik und Poliklinik der Universität Würzburg, Josef-Schneider-Strasse 11, Würzburg, Germany. m.buttmann@uni-wuerzburg.de
M
M
Buttmann
H
H
Wiendl
D000074323:Alemtuzumab; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016543:Central Nervous System Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab; D009894:Opportunistic Infections / Q000209:etiology; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000069442:Natalizumab; D011994:Recombinant Proteins; D000074323:Alemtuzumab; D000069283:Rituximab
Therapeutische monoklonale Antikörper in der Neurologie.